Results 151 to 160 of about 308,115 (327)

Oxidation of Ranitidine by Isozymes of Flavin-Containing Monooxygenase and Cytochrome P450

, 2000
Woon‐Gye Chung, Chang‐Shin Park, Hyung‐Keun Roh, Woon-Kee Lee, Young‐Nam Cha   +4 more
openalex   +1 more source

Chemical engineering as an essential element of industrial biotechnology in Mexico: New aims in research and university education

The Canadian Journal of Chemical Engineering, EarlyView.
Abstract On the centennial of higher education in Chemical Engineering in Mexico, it is pertinent to revisit the key stages that have contributed to its consolidation as a vital discipline for the nation's scientific and technological advancement. Although the initial mission of chemical engineering education was primarily oriented toward the training ...
Agustín López Munguía, Octavio T. Ramírez, Rafael Vazquez‐Duhalt, Eduardo Bárzana   +3 more
wiley   +1 more source

Tuning architectural organization of eukaryotic P450 system to boost bioproduction in Escherichia coli

Nature Communications
Eukaryotic cytochrome P450 enzymes, generally colocalizing with their redox partner cytochrome P450 reductase (CPR) on the cytoplasmic surface of organelle membranes, often perform poorly in prokaryotic cells, whether expressed with CPR as a tandem ...
Yikui Li, Jie Li, Wei-Kang Chen, Yang Li, Sheng Xu, Linwei Li, Bing Xia, Ren Wang   +7 more
doaj   +1 more source

Reaction ofMycobacterium tuberculosisCytochrome P450 Enzymes with Nitric Oxide

, 2009
Hugues Ouellet, Jérôme Lang, Manon Couture, Paul R. Ortiz de Montellano   +3 more
openalex   +1 more source

Hepatic, Extrahepatic and Extracellular Vesicle Cytochrome P450 2E1 in Alcohol and Acetaminophen-Mediated Adverse Interactions and Potential Treatment Options [PDF]

, 2022
Santosh Kumar, Bhupesh Singla, Ajay Kumar Singh, Stacey M. Thomas-Gooch, Kaining Zhi, Udai P. Singh   +5 more
openalex   +1 more source

A Phase 1, Randomized, Placebo‐Controlled, Multiple‐Dose, Double‐Blind Study to Evaluate and Compare the Pharmacokinetics and Safety of Rimegepant in Healthy Adult Japanese and Caucasian Individuals

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This Phase 1, randomized, placebo‐controlled, double‐blind study assessed the pharmacokinetic profile of rimegepant (25, 75, or 150 mg once daily for 14 days) in healthy Japanese and Caucasian adults. Exposures were modestly increased in Japanese participants compared with Caucasian participants following a single dose of rimegepant (Day 1 ...
Rajinder Bhardwaj, Chay Ngee Lim, Yinhua Li, Kyle T. Matschke, Richard Bertz, Robert Croop, Jing Liu   +6 more
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Induction of cytochrome P450 family 1 mRNAs and activities in a cell line from the frog Xenopus laevis

, 2012
Daniel V. Iwamoto, Chad M. Kurylo, Kelly M. Schorling, Wade H. Powell   +3 more
openalex   +2 more sources

Arsenic: Various species with different effects on cytochrome P450 regulation in humans

, 2021
Mahmoud A. El‐Ghiaty, Ayman O.S. El‐Kadi   +1 more
openalex   +2 more sources

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation

Clinical Pharmacology &Therapeutics, EarlyView.
From the nationwide multicenter consortium, 8,163 patients undergoing drug‐eluting stent implantation were classified according to the presence of the CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P2A2RC and TRS 2°P scores ...
Hyun Woong Park, Jae‐Hwan Lee, Jin‐Ok Jeong, Diana A. Gorog, Udaya S. Tantry, Byeong‐Keuk Kim, Hyung Joon Joo, Kiyuk Chang, Jin‐Yong Hwang, Young Bin Song, Sung Gyun Ahn, Jung‐Won Suh, Woong Gil Choi, Jung Rae Cho, Jeehoon Kang, Sang Yeub Lee, Hyo‐Soo Kim, Moo Hyun Kim, Do‐Sun Lim, Eun‐Seok Shin, Paul A. Gurbel, Young‐Hoon Jeong, on behalf of the PTRG‐DES Consortium Investigators   +22 more
wiley   +1 more source